US 2003/0215898 A1 · Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Abstract

The present invention relates to methods for using a human cyclic nucleotide phosphodiesterase belonging to the superfamily of mammalian phosphodiesterases. The invention also relates to methods for using polynucleotides encoding the phosphodiesterase. The invention relates to methods using the phosphodiesterase polypeptides and polynucleotides as a target for diagnosis and treatment in phosphodiesterase-mediated or -related disorders. The invention further relates to drug-screening methods using the phosphodiesterase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the phosphodiesterase polypeptides and polynucleotides. The invention further relates to agonists and antagonists identifiefd by drug screening methods with the phosphodiesterase polypeptides and polynucleotides as a target.

Claims12

Dependent claims

A method of identifying an inhibitor of a human cyclic phosphodiesterase protein comprising:

a) combining an agent to be tested with a host cell expressing human cyclic phosphodiesterase protein having an amino acid sequence as set forth in SEQ ID NO:1 under conditions suitable for detecting a phosphodiesterase activity;
and
b) assessing the ability of the agent to inhibit the phosphodiesterase activity, whereby inhibition of the phosphodiesterase activity by the agent is indicative that the agent is an inhibitor;
wherein the host cell is selected from the group consisting of breast carcinoma cells and colon carcinoma cells.

1 more element

Dependencies are inferred from the claim text.

Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Life of this patent

Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Life of this patent

Abstract

Claims12